2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene raised 2026 adjusted EPS guidance to above $4.80 from above $3.40, implying more than 130.8% growth versus 2025, while lifting revenue guidance to $193.5-$197.5 billion; its shares are up 68.7% year to date and trade at a 13.58x forward P/E. Archer-Daniels-Midland raised 2026 adjusted EPS guidance to $5.15-$5.60 from $4.15-$4.70, supported by improved crushing and ethanol conditions, renewable-fuel obligations, trade dynamics and energy prices. ADM shares have gained 50.4% year to date, with consensus 2026 EPS estimates up 8.5% over 60 days, while Centene's current-year estimate rose 40.9%.

Analysis

CNC's re-rating now depends less on top-line growth and more on whether medical-cost discipline is sustainable. A 50-100bp adverse swing in the health-benefits ratio can absorb a meaningful portion of the implied earnings recovery, making state Medicaid rate adequacy, acuity trends and redetermination-related mix the critical quarterly variables. The market may continue to reward margin restoration over the next 1-3 months, but the 6-18 month risk is that peers such as MOH and ELV compete away pricing gains at state contract renewals or that utilization normalizes above pricing assumptions.

ADM is a more cyclical policy-and-spread trade than a conventional low-multiple value story. Incremental ethanol economics and oilseed-crushing margins have high operating leverage, but those profits can reverse quickly if corn basis rises, renewable-fuel economics weaken, or trade flows normalize; Bunge (BG) and Ingredion (INGR) are the closest read-throughs. The key contrarian point is that a large earnings reset tied to favorable external margins deserves a lower terminal multiple unless management demonstrates that cost savings and Nutrition growth offset normalization.

The article's valuation framing is not independently sufficient after sharp price appreciation: verify the guidance bridge, quarterly run-rate margins, buyback assumptions and consensus EPS definition before adding exposure. Near-term upside is most plausible around subsequent estimate revisions; downside can be abrupt if either company merely reiterates rather than raises guidance, because current expectations already embed unusually strong earnings recovery.

Key Decisions for Investors

• Initiate a modest long CNC only on confirmation that the next quarterly health-benefits ratio is within management's target range and Medicaid rate actions cover acuity trends. Target a 10-15% relative return over 3-6 months from further estimate revisions; exit if the ratio deteriorates by more than 75bp versus guidance or 2027 EPS consensus begins declining.
• Use CNC as a relative-value long versus MOH rather than an outright healthcare-beta position over 3-6 months. CNC has the cleaner margin-restoration setup, while the trade is invalidated if MOH shows superior rate adequacy or CNC's membership/revenue mix deteriorates after redeterminations.
• Treat ADM as a tactical 1-3 month long only while ethanol and crush spreads remain constructive; express with a defined-risk call spread rather than chasing spot after the rally. Take profits following the next guidance confirmation, and cut exposure if corn/energy input costs compress ethanol margins or RFS implementation is delayed or diluted.
• Do not underwrite ADM on a permanent valuation discount thesis. Set an alert for quarterly segment profit: if Ag Services & Oilseeds and Carbohydrate Solutions fail to translate favorable spreads into sequential margin expansion, rotate exposure to BG or remain neutral rather than averaging down.